Combined effects of PPARγ2 P12A and PPARα L162V polymorphisms on glucose and insulin homeostasis: The Québec Family Study

Journal of Human Genetics

Volumn 48, Issue 12, 2003, Pages 614-621

  Bossé, Yohan ^a,b   Weisnagel, S John ^a,b   Bouchard, Claude ^c   Després, Jean Pierre ^a,b,d   Pérusse, Louis ^b   Vohl, Marie Claude ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

C peptide; Epistasis; Insulin homeostasis; OGTT; Peroxisome proliferator activated receptors; PPAR L162V mutation; PPAR 2 P12A mutation; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; UNCLASSIFIED DRUG; CELL RECEPTOR; PEPTIDE; TRANSCRIPTION FACTOR;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL GENETICS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; LIPID METABOLISM; MALE; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; AGE; CHEMISTRY; FAMILY HEALTH; GENETIC POLYMORPHISM; GENETICS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; METABOLISM; MIDDLE AGED; MUTATION; PHENOTYPE; TIME;

ADULT; AGE FACTORS; AREA UNDER CURVE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; MALE; MIDDLE AGED; MUTATION; PEPTIDES; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 0347419153     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-003-0087-2     Document Type: Article

References (39)

1. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, et al (2000) The common PPAR-gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
2. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435
3. Bouchard C (1996) Genetic epidemiology, association, and sib-pair linkage: results from the Quebec Family Study. In: Bray GA, Ryan DH (eds) Molecular and genetic aspects of obesity, vol 5, Louisiana State University Press, Baton Rouge, pp 470-481
4. Bruning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR (1997) Development of a novel polygenic model of NID-DM in mice heterozygous for IR and IRS-1 null alleles. Cell 88:561-572
5. Busch CP, Hegele RA (2001) Genetic determinants of type 2 diabetes mellitus. Clin Genet 60:243-254
6. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
7. Desbuquois B, Aurbach GD (1971) Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732-738
8. Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA (2001) A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med 79:198-204
9. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, et al (2000) Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43:673-680
10. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, et al (2000) Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642
11. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, et al (2001) PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50:2809-2814
12. Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 [Suppl 2]:10-15
13. Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-548
14. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM (2000) Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 85:2014-2019
15. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45-61
16. Hsueh WC, Cole SA, Shuldiner AR, Beamer BA, Blangero J, Hixson JE, MacCluer JW, et al (2001) Interactions between variants in the beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes and obesity. Diabetes Care 24:672-677
17. Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
18. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489-1498
19. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431
20. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Renn W, et al (1999) The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42:758-762
21. Lacquemant C, Lepretre F, Pineda Torra I, Manraj M, Charpentier G, Ruiz J, Staels B, et al (2000) Mutation screening of the PPARalpha gene in type 2 diabetes associated with coronary heart disease. Diabetes Metab 26:393-401
22. Leone TC, Weinheimer CJ, Kelly DP (1999) A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 96:7473-7478
23. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V (1999) Pro12Ala substitution in the peroxisome proliferator-activated receptor- gamma2 is not associated with type 2 diabetes. Diabetes 48:1466-1468
24. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839
25. Miles PD, Barak Y, He W, Evans RM, Olefsky JM (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105:287-292
26. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, et al (2001) The Pro12 - > Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50:891-894
27. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD (1987) Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia 30:763-768
28. Richterich R, Dauwalder H (1971) [Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method]. Schweiz Med Wochenschr 101:615-618
29. Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, et al (2000) The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 10:321-333
30. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, et al (2002) Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384
31. Schoonjans K, Martin G, Staels B, Auwerx J (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8:159-166
32. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093
33. Stefan N, Fritsche A, Haring H, Stumvoll M (2001) Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene. Diabetes 50:1143-1148
34. Stumvoll M, Haring H (2002a) The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 51:2341-2347
35. Stumvoll M, Haring H (2002b) Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2? Diabetologia 45:152-153
36. Stumvoll M, Stefan N, Fritsche A, Madaus A, Tschritter O, Koch M, Machicao F, et al (2002c) Interaction effect between common polymorphisms in PPARgamma(2) (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity. J Mol Med 80:33-38
37. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, et al (2000) Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945-952
38. Walczak R, Tontonoz P (2002) PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 43:177-186
39. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, et al (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270-274